AstraZeneca is ramping up in cell therapy after a late entrance to the field. In 2022, it made its first significant acquisition in the area, buying up privately held Neogene Therapeutics. And the follow year, it formed a partnership with Quell Therapeutics to work on cell therapies for autoimmune diseases. The company has also struck development deals with AbelZeta in China and Cellectis.
At the same time, AstraZeneca has been exploring gene therapy, acquiring gene editing specialist LogicBio Therapeutics in 2022 and then inking a deal worth as much as $1 billion to acquire early-stage gene therapy programs and related technologies from Pfizer.
